• About
    • Login
    View Item 
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    •   Institutional Repository Home
    • Electronic Theses and Dissertations
    • Electronic Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of Institutional RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDepartmentThis CollectionBy Issue DateAuthorsTitlesSubjectsDepartment

    My Account

    LoginRegister

    Development and Application of Antibody Discovery Technologies For Diverse Viral Pathogens

    Shiakolas, Andrea Raye
    0000-0001-9391-5434
    : http://hdl.handle.net/1803/17348
    : 2022-03-24

    Abstract

    Existing viral pathogens like human immunodeficiency virus (HIV), influenza virus, and coronaviruses, along with emerging infectious diseases, are constant worldwide threats, causing illness and death for millions of people each year. Studying the immune response to these pathogens, and specifically the antibody response, can guide the development of vaccines and therapeutic tools to prevent and treat these diseases. To efficiently and effectively screen B cells in order to characterize the antibody response, I helped develop an antibody discovery technology termed LIBRA-seq (Linking B cell receptor to antigen specificity through sequencing). LIBRA-seq allows for high throughput determination of antibody sequence and antigen specificity at the single cell level. First, I tested and validated the technology using cell lines with known B cell receptor sequences and specificities and demonstrated that LIBRA-seq could successfully discriminate diverse antigen reactivity patterns. Next, I used LIBRA-seq to identify broadly neutralizing HIV and influenza antibodies from HIV infection samples. Additionally, I characterized broadly reactive coronavirus antibodies from a SARS-CoV recovered donor. Further, I extended the LIBRA-seq technology to include a functional readout from sequencing data by including a viral protein and its receptor in the antigen screening library. I tested this idea with SARS-CoV-2 spike protein and the ACE2 receptor and showed high rates of neutralizing antibody discovery. These experiments highlighted the power and utility of LIBRA-seq while contributing discovery of novel antibodies to the field. Overall, the application of LIBRA-seq to diverse viral pathogens has led to analysis of antibody repertoires, and discovery of novel antibodies, enhancing our knowledge of antibody-antigen interactions and elucidating viral epitopes, all of which ultimately aid in vaccine design and therapeutic development.
    Show full item record

    Files in this item

    Icon
    Name:
    SHIAKOLAS-DISSERTATION-2022.pdf
    Size:
    32.21Mb
    Format:
    PDF
    View/Open

    This item appears in the following collection(s):

    • Electronic Theses and Dissertations

    Connect with Vanderbilt Libraries

    Your Vanderbilt

    • Alumni
    • Current Students
    • Faculty & Staff
    • International Students
    • Media
    • Parents & Family
    • Prospective Students
    • Researchers
    • Sports Fans
    • Visitors & Neighbors

    Support the Jean and Alexander Heard Libraries

    Support the Library...Give Now

    Gifts to the Libraries support the learning and research needs of the entire Vanderbilt community. Learn more about giving to the Libraries.

    Become a Friend of the Libraries

    Quick Links

    • Hours
    • About
    • Employment
    • Staff Directory
    • Accessibility Services
    • Contact
    • Vanderbilt Home
    • Privacy Policy